CD19 and non-Hodgkin lymphoma: Similar findings were noted in 38 patients (ALL and NHL) treated with CD-19 directed CAR-T therapy with neutropenia noted in 62%, thrombocytopenia in 44%, and anemia in 17% of patients at 6 weeks post CAR-T cell infusion [25].